Scott Tarriff (Lead Director)
President and CEO, Eagle Pharmaceuticals, Inc.
Scott Tarriff is the founder of Eagle Pharmaceuticals, Inc., a publicly traded company, and has served as President and Chief Executive Officer and as a member of its board of directors since its inception. Mr. Tarriff has grown Eagle Pharmaceuticals from a privately financed pharmaceutical development company to an established, publicly traded, specialty pharmaceutical company. Prior to forming Eagle, Mr. Tariff held various executive positions at Par Pharmaceutical Companies, Inc., a publicly-traded developer, manufacturer and marketer of specialty pharmaceuticals, including as president and chief executive officer from September 2003 to September 2006, after joining Par in 1998. Mr. Tarriff also served on Par’s board of directors from 2002 to September 2006. Prior to that, Mr. Tarriff held various positions with Bristol-Meyers Squibb, a publicly-traded biopharmaceutical company, including senior director-marketing. Mr. Tarriff has served as a director of Synthetic Biologics, Inc., a publicly-traded biotechnology company, since February 2012 and previously served on the board of directors of Clinical Data, Inc., a publicly-traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc. Mr. Tarriff holds a B.S. in marketing from Pennsylvania State University and an M.B.A. from Rider College.
Scott Braunstein, M.D.
Operating Partner, Aisling Capital
Dr. Braunstein is an Operating Partner at Aisling Capital, a leading investment firm. He held leadership roles including Chief Operating Officer, Chief Strategy Officer and Senior Vice President of Strategy at Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the clinical and commercial development of new products utilized in acute patient care. Earlier in his career, Dr. Braunstein held positions in finance at Everpoint Asset Management and J.P. Morgan Asset Management. He began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and for Columbia University Medical Center after completing his training at the New York Hospital/Cornell Medical Center, his research experience at Rockefeller University, and earning his medical degree from the Albert Einstein College of Medicine.
James A. Cannon
Chief Financial Officer and Vice Chairman, BBDO
James A. Cannon is vice chairman, chief financial officer and a member of the board of directors of BBDO Worldwide. In this capacity, he oversees the financial management of BBDO operations in 77 countries. Mr. Cannon joined BBDO in 1967, was promoted to chief financial officer of the agency in 1984, and was elected to its board of directors one year later. An integral member of the team that formed Omnicom Group via a unique three-agency merger of BBDO, DDB and Needham Harper & Steers, Mr. Cannon became comptroller of the new group and a member of its board of directors in 1986, a position he held through 2002. In 1987, he was appointed director of financial operations of the Omnicom Group, serving in this capacity until early 1989 when he rejoined BBDO Worldwide as executive vice president and chief financial officer. His return was concurrent with that of Allen Rosenshine who became chairman and chief executive officer of BBDO after heading Omnicom Group. Mr. Cannon was promoted to vice chairman of the agency in 1990. Mr. Cannon is a graduate of Pace University in the City of New York and Westchester County and served in the United States Marine Corps.
Chief Operating Officer, Scholar Rock
As chief operating officer and head of corporate development since 2014 at Scholar Rock, Mr. Ezickson leads corporate development, operations and administration and execution of corporate strategy for this Cambridge, MA-based clinical-stage biotechnology company. He plays a significant role in corporate finance at Scholar Rock, which raised $86 million in its IPO in June 2018. Prior to joining Scholar Rock, Mr. Ezickson served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals, Inc., where he worked from 2003 to July 2013. From 1994 to 2003, he worked at Biogen Inc. in roles that included President of Biogen Canada, Program Executive and Associate General Counsel. Elan holds a B.A. in political science from Yale University and a J.D. from the Columbia University School of Law.
Chief Financial Officer, Paratek Pharmaceuticals
As chief financial officer at Paratek Pharmaceuticals, a Boston-based biopharmaceutical company approaching commercialization of its lead asset, Mr. Pagán has played the leading role in the company’s financial strategy since 2014, during which time it has raised well over $500 million from the public markets. Prior to joining Paratek, he was Vice President, Finance at Acceleron Pharma Inc., where he was instrumental in the company’s successful IPO as well as multiple rounds of private and public equity and debt financings. Prior to working at Acceleron, Mr. Pagán served in strategic and financial management roles at Biogen Idec and Bristol-Myers Squibb. Previously, Mr. Pagán was an investment banker in J.P. Morgan’s Healthcare group, and he held a number of pharmaceutical operational roles at Johnson and Johnson. Mr. Pagán received his BSE in chemical engineering from Princeton University and his MBA from Columbia Business School.